Guardant Health (NASDAQ:GH) Stock Purchase Disclosed by Rep. Jonathan L. Jackson

Key Points

• Rep. Jonathan L. Jackson purchased $15,001–$50,000 of Guardant Health shares on September 28 through a Morgan Stanley trust account. He also bought Estee Lauder and Datadog while selling Viasat and Walmart.
• Guardant Health reported quarterly revenue of $334.98 million, up 44.3% year over year, and an adjusted loss of $0.42 per share—better than analysts’ expectations. The stock recently opened at $162.59, with a 52-week range of $66.59 to $191.05.
• Analysts maintain a broadly positive outlook, with a consensus “Moderate Buy” rating and an average price target of $190.00. Institutional investors own 92.6% of the company, while insiders have sold approximately $30.1 million of shares over the past three months.

Representative Jonathan L. Jackson (Democratic-Illinois) recently bought shares of Guardant Health, Inc. NASDAQ: GH. In a filing disclosed on October 19th, the Representative disclosed that they had bought between $15,001 and $50,000 in Guardant Health stock on September 28th. The trade occurred in the Representative's "MORGAN STANLEY TRUST ACCOUNT" account.

Representative Jonathan L. Jackson also recently made the following trade(s):

• Purchased $50,001 - $100,000 in shares of Estee Lauder Companies NYSE: EL on 9/28/2026.
• Sold $50,001 - $100,000 in shares of Viasat NASDAQ: VSAT on 9/28/2026.
• Sold $50,001 - $100,000 in shares of Walmart NASDAQ: WMT on 9/28/2026.
• Purchased $50,001 - $100,000 in shares of Datadog NASDAQ: DDOG on 9/28/2026.
• Sold $1,001 - $15,000 in shares of Tortoise Energy Infrastructure NYSE: TYG on 9/4/2026.
• Sold $1,001 - $15,000 in shares of Viasat NASDAQ: VSAT on 8/28/2026.

Guardant Health Stock Performance

Shares of GH stock opened at $162.59 on Wednesday. Guardant Health, Inc. has a fifty-two week low of $66.59 and a fifty-two week high of $191.05. The stock has a 50 day moving average price of $167.70 and a two-hundred day moving average price of $140.50. The company has a market capitalization of $21.82 billion, a P/E ratio of -46.59 and a beta of 1.58.

Guardant Health (NASDAQ:GH - Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share for the quarter, beating analysts' consensus estimates of ($0.76) by $0.34. The company had revenue of $334.98 million for the quarter, compared to analysts' expectations of $314.23 million. During the same period last year, the company posted ($0.44) EPS. The business's revenue for the quarter was up 44.3% compared to the same quarter last year. As a group, equities analysts predict that Guardant Health, Inc. will post -3.02 earnings per share for the current year.

Analysts Set New Price Targets

GH has been the subject of several analyst reports. Barclays increased their price target on shares of Guardant Health from $200.00 to $220.00 and gave the company an "overweight" rating in a research report on Wednesday, October 7th. TD Cowen reissued a "buy" rating on shares of Guardant Health in a report on Tuesday, August 25th. Royal Bank Of Canada boosted their price objective on shares of Guardant Health from $185.00 to $200.00 and gave the company an "outperform" rating in a research report on Friday, July 31st. Guggenheim upped their price objective on shares of Guardant Health from $190.00 to $200.00 and gave the company a "buy" rating in a research note on Thursday, October 1st. Finally, Evercore reaffirmed an "outperform" rating and set a $200.00 price objective on shares of Guardant Health in a research note on Monday, July 6th. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $190.00.

Hedge Funds Weigh In On Guardant Health

Hedge funds and other institutional investors have recently made changes to their positions in the business. Allworth Financial LP boosted its position in shares of Guardant Health by 12.4% during the second quarter. Allworth Financial LP now owns 1,072 shares of the company's stock valued at $161,000 after purchasing an additional 118 shares in the last quarter. GAMMA Investing LLC grew its stake in Guardant Health by 14.5% in the second quarter. GAMMA Investing LLC now owns 965 shares of the company's stock worth $145,000 after purchasing an additional 122 shares during the period. First Pacific Financial raised its holdings in Guardant Health by 33.1% in the first quarter. First Pacific Financial now owns 559 shares of the company's stock worth $52,000 after purchasing an additional 139 shares in the last quarter. V Square Quantitative Management LLC raised its holdings in Guardant Health by 55.3% in the third quarter. V Square Quantitative Management LLC now owns 407 shares of the company's stock worth $73,000 after purchasing an additional 145 shares in the last quarter. Finally, ABS Investment Management LLC bought a new position in Guardant Health in the second quarter worth $345,069,000. Institutional investors own 92.60% of the company's stock.

Insider Buying and Selling at Guardant Health

In other news, CTO Darya Chudova sold 7,738 shares of the company's stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $178.00, for a total value of $1,377,364.00. Following the sale, the chief technology officer directly owned 70,635 shares of the company's stock, valued at $12,573,030. This represents a 9.87% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Terilyn Monroe sold 46,300 shares of Guardant Health stock in a transaction dated Wednesday, August 12th. The shares were sold at an average price of $165.12, for a total transaction of $7,645,056.00. Following the transaction, the insider directly owned 22,979 shares of the company's stock, valued at approximately $3,794,292.48. This trade represents a 66.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 178,940 shares of company stock valued at $30,070,911. Company insiders own 5.60% of the company's stock.

About Representative Jackson

Jonathan Jackson (Democratic Party) is a member of the U.S. House, representing Illinois' 1st Congressional District. He assumed office on January 3, 2023. His current term ends on January 3, 2027. Jackson (Democratic Party) is running for re-election to the U.S. House to represent Illinois' 1st Congressional District. He declared candidacy for the 2026 election. Jonathan Jackson was born in Chicago, Illinois. Jackson graduated from Whitney Young High School. He earned an M.B.A. from Northwestern University. Jackson's career experience includes working as an investment analyst and an entrepreneur.

About Guardant Health

Guardant Health, Inc NASDAQ: GH is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.

The company's products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient's response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.